A Multi-Center, Open-Label Study of the Human Anti-TNF Monoclonal Antibody Adalimumab to Evaluate Long-Term Safety and Tolerability of Repeated Administration of Adalimumab in Pediatric Subjects with Ulcerative Colitis Who Completed the Study M11-290
CompletedCTIS2023-504711-32-00
AbbVie Deutschland GmbH & Co. KGUlcerative Colitis
Start: 2015-11-24End: 2025-04-08Target: 46Updated: 2025-06-13